290 related articles for article (PubMed ID: 28057111)
1. [Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China].
Qiu YP; Zhao K; Li X; Shi LW; Guo WD; Qi XR; Sui BY; Zhou RM
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1074-1078. PubMed ID: 28057111
[No Abstract] [Full Text] [Related]
2. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
Hoshi SL; Kondo M; Okubo I
PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F
Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation.
Kebede TT; Svensson M; Addissie A; Trollfors B; Andersson R
BMC Public Health; 2019 Aug; 19(1):1078. PubMed ID: 31399030
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China.
Zhao D; Gai Tobe R; Cui M; He J; Wu B
Vaccine; 2016 Dec; 34(50):6158-6165. PubMed ID: 27838068
[TBL] [Abstract][Full Text] [Related]
6. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.
Kuchenbecker U; Chase D; Reichert A; Schiffner-Rohe J; Atwood M
PLoS One; 2018; 13(5):e0197905. PubMed ID: 29795647
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.
Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE
Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
10. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil.
de Soárez PC; Sartori AM; Freitas AC; Nishikawa ÁM; Novaes HM
PLoS One; 2015; 10(6):e0130217. PubMed ID: 26114297
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
Mo X; Gai Tobe R; Liu X; Mori R
Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
[TBL] [Abstract][Full Text] [Related]
15. Impact and cost effectiveness of pneumococcal conjugate vaccine in India.
Krishnamoorthy Y; Eliyas SK; Nair NP; Sakthivel M; Sarveswaran G; Chinnakali P
Vaccine; 2019 Jan; 37(4):623-630. PubMed ID: 30587430
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].
De Graeve D; Verhaegen J; Ament A; Baltussen R
Acta Clin Belg; 2000; 55(5):257-65. PubMed ID: 11109640
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China.
Sun X; Tang Y; Ma X; Guo X; Huang Z; Ren J; Qiu J; Jiang H; Lu Y
Front Public Health; 2021; 9():647725. PubMed ID: 34109145
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.
Sisk JE; Moskowitz AJ; Whang W; Lin JD; Fedson DS; McBean AM; Plouffe JF; Cetron MS; Butler JC
JAMA; 1997 Oct 22-29; 278(16):1333-9. PubMed ID: 9343464
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.
Jiang Y; Yang X; Taniguchi K; Petigara T; Abe M
J Med Econ; 2018 Jul; 21(7):687-697. PubMed ID: 29723081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
